Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.67
OMER's Cash-to-Debt is ranked lower than
81% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. OMER: 0.67 )
Ranked among companies with meaningful Cash-to-Debt only.
OMER' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.21  Med: 1.21 Max: N/A
Current: 0.67
Equity-to-Asset -0.31
OMER's Equity-to-Asset is ranked lower than
94% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. OMER: -0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
OMER' s Equity-to-Asset Range Over the Past 10 Years
Min: -15.24  Med: -0.26 Max: 0.7
Current: -0.31
-15.24
0.7
Piotroski F-Score: 5
Altman Z-Score: -7.08
Beneish M-Score: 2.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -170.85
OMER's Operating Margin % is ranked lower than
62% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. OMER: -170.85 )
Ranked among companies with meaningful Operating Margin % only.
OMER' s Operating Margin % Range Over the Past 10 Years
Min: -12988.5  Med: -1430.21 Max: -170.85
Current: -170.85
-12988.5
-170.85
Net Margin % -189.16
OMER's Net Margin % is ranked lower than
65% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. OMER: -189.16 )
Ranked among companies with meaningful Net Margin % only.
OMER' s Net Margin % Range Over the Past 10 Years
Min: -13668.46  Med: -1389.6 Max: -189.16
Current: -189.16
-13668.46
-189.16
ROA % -136.47
OMER's ROA % is ranked lower than
89% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. OMER: -136.47 )
Ranked among companies with meaningful ROA % only.
OMER' s ROA % Range Over the Past 10 Years
Min: -538.37  Med: -97.57 Max: -50.37
Current: -136.47
-538.37
-50.37
ROC (Joel Greenblatt) % -5940.95
OMER's ROC (Joel Greenblatt) % is ranked lower than
84% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. OMER: -5940.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OMER' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8254.24  Med: -2907.87 Max: -2046.97
Current: -5940.95
-8254.24
-2046.97
3-Year Revenue Growth Rate 13.10
OMER's 3-Year Revenue Growth Rate is ranked higher than
66% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. OMER: 13.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OMER' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -18.75 Max: 13.1
Current: 13.1
0
13.1
3-Year EBITDA Growth Rate 8.00
OMER's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. OMER: 8.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OMER' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -9.05 Max: 21.2
Current: 8
0
21.2
3-Year EPS without NRI Growth Rate 7.90
OMER's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. OMER: 7.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OMER' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -8.9 Max: 19.8
Current: 7.9
0
19.8
GuruFocus has detected 4 Warning Signs with Omeros Corp $OMER.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OMER's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

OMER Guru Trades in Q3 2015

Paul Tudor Jones 13,000 sh (New)
Jim Simons 12,593 sh (-90.76%)
» More
Q4 2015

OMER Guru Trades in Q4 2015

Joel Greenblatt 10,225 sh (New)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2016

OMER Guru Trades in Q1 2016

Joel Greenblatt 19,241 sh (+88.18%)
» More
Q2 2016

OMER Guru Trades in Q2 2016

Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OMER

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:INO, NAS:MESO, NAS:PACB, NAS:IMMU, NAS:SPPI, NAS:ACHN, NAS:KERX, NAS:ESPR, NAS:CERS, NAS:AVDL, OTCPK:ABVC, OTCPK:IPHYF, NAS:CYTK, NAS:NLNK, NAS:BCRX, NAS:CLDX, NAS:TLGT, NAS:VNDA, NAS:NVAX, NAS:FOMX » details
Traded in other countries:3O8.Germany,
Omeros Corp is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system.

Omeros Corp was incorporated on June 16, 1994. The Company is engaged in the discovery, development and commercialization of pharmaceutical products for inflammation, coagulopathies and disorders of the central nervous system. Its product OMS302 or Omidria completed its Phase 3 clinical trial is used for lens replacement surgery and is derived from its PharmacoSurgery platform designed to improve clinical outcomes of patients undergoing ophthalmological, arthroscopic, urological and other surgical and medical procedures. It has six clinical-stage programs in its pipeline; OMS103 for inflammatory pain following arthroscopic partial meniscectomy surgery, which has completed one Phase 3 trial, its PDE10 inhibitor OMS824 for schizophrenia, which is in a Phase 2 clinical program for patients with stable schizophrenia, its PDE10 inhibitor OMS824 for Huntington's disease, which is in Phase 2 clinical program, its MASP-2 antibody OMS721 for the treatment of thrombotic microangiopathies, which has completed dosing in Phase 1 clinical trial and a Phase 2 clinical program is underway, its PPARγ program, in which three Phase 2 clinical trials are being conducted by its collaborators to evaluate a PPARγ agonist, alone or in combination with other agents, for treatment of addiction to opioids and to nicotine and its PharmacoSurgery product OMS201 for use during urological procedures, including uroendoscopic procedures, that has completed a Phase 1/Phase 2 clinical trial in 2010 and is not currently in active clinical trials. The Company is subject to regulate under the U.S. and EU governing regulations.

Ratios

vs
industry
vs
history
PS Ratio 13.46
OMER's PS Ratio is ranked lower than
57% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. OMER: 13.46 )
Ranked among companies with meaningful PS Ratio only.
OMER' s PS Ratio Range Over the Past 10 Years
Min: 8.14  Med: 36.97 Max: 1667.33
Current: 13.46
8.14
1667.33
Current Ratio 3.78
OMER's Current Ratio is ranked higher than
54% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. OMER: 3.78 )
Ranked among companies with meaningful Current Ratio only.
OMER' s Current Ratio Range Over the Past 10 Years
Min: 0.41  Med: 2.12 Max: 6.61
Current: 3.78
0.41
6.61
Quick Ratio 3.69
OMER's Quick Ratio is ranked higher than
56% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. OMER: 3.69 )
Ranked among companies with meaningful Quick Ratio only.
OMER' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 2.01 Max: 6.61
Current: 3.69
0.41
6.61
Days Inventory 305.55
OMER's Days Inventory is ranked lower than
86% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. OMER: 305.55 )
Ranked among companies with meaningful Days Inventory only.
OMER' s Days Inventory Range Over the Past 10 Years
Min: 182.32  Med: 182.32 Max: 305.55
Current: 305.55
182.32
305.55
Days Sales Outstanding 107.86
OMER's Days Sales Outstanding is ranked lower than
75% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. OMER: 107.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
OMER' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.06  Med: 86.46 Max: 265.45
Current: 107.86
36.06
265.45
Days Payable 1.00
OMER's Days Payable is ranked lower than
99% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 56.51 vs. OMER: 1.00 )
Ranked among companies with meaningful Days Payable only.
OMER' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 2253.81 Max: 2253.81
Current: 1
1
2253.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.70
OMER's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. OMER: -13.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OMER' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -98.1  Med: -12.6 Max: 0
Current: -13.7
-98.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.36
OMER's Price-to-Median-PS-Value is ranked higher than
86% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. OMER: 0.36 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OMER' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.18 Max: 44.25
Current: 0.36
0.33
44.25
Earnings Yield (Greenblatt) % -11.13
OMER's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. OMER: -11.13 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OMER' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -11.7  Med: 381.25 Max: 1464.3
Current: -11.13
-11.7
1464.3

More Statistics

Revenue (TTM) (Mil) $35.39
EPS (TTM) $ -1.72
Beta4.05
Short Percentage of Float25.16%
52-Week Range $7.20 - 16.80
Shares Outstanding (Mil)42.92

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 39 67 139 218
EPS ($) -1.65 -1.29 -0.03 1.01
EPS without NRI ($) -1.65 -1.29 -0.03 1.01
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for OMER

Headlines

Articles On GuruFocus.com
Wedbush Highlights 2015 Catalysts for Emerging BioPharmaceuticals Feb 04 2015 
Follow Up on a Speculative Options Bet May 27 2011 
Another Two Speculative Options Bets May 13 2011 

More From Other Websites
Omeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : February 8, 2017 Feb 08 2017
ETFs with exposure to Omeros Corp. : January 19, 2017 Jan 19 2017
ETFs with exposure to Omeros Corp. : January 3, 2017 Jan 03 2017
Omeros Corp. – Value Analysis (NASDAQ:OMER) : December 23, 2016 Dec 23 2016
Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : December 22, 2016 Dec 22 2016
ETFs with exposure to Omeros Corp. : December 19, 2016 Dec 19 2016
Is AG Mortgage Investment Trust Inc (MITT) Going to Burn Investors? Dec 15 2016
Omeros Corp. breached its 50 day moving average in a Bearish Manner : OMER-US : December 9, 2016 Dec 09 2016
Ennis, Inc. (EBF): Are Hedge Funds Right About This Stock? Dec 09 2016
Data from Omeros’ OMS721 Phase 2 Clinical Trial in Patients with Stem Cell Transplant-Associated... Dec 07 2016
Omeros Extending Compassionate Use for Pediatric Patient No Longer Requiring Dialysis after OMS721... Dec 06 2016
ETFs with exposure to Omeros Corp. : December 5, 2016 Dec 05 2016
Omeros’ Proprietary Orphan GPCR Program Delivers New Target and Approach in Cancer Immunotherapy Dec 05 2016
International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2... Dec 01 2016
International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2... Nov 30 2016
International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2... Nov 30 2016
ETFs with exposure to Omeros Corp. : November 23, 2016 Nov 23 2016
Omeros Corp. :OMER-US: Earnings Analysis: Q3, 2016 By the Numbers : November 21, 2016 Nov 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)